Goiter Endemik

01Pathophysiology

Endemic goiter results from chronic dietary iodine deficiency, the single most common cause of goiter worldwide. Iodine is an essential substrate for thyroid hormone synthesis. When intake falls below approximately 50 mcg/day, the thyroid gland cannot produce adequate thyroxine (T4) and triiodothyronine (T3).

The drop in circulating thyroid hormones triggers a compensatory increase in TSH secretion from the anterior pituitary. Sustained TSH elevation stimulates thyroid follicular cell hyperplasia and hypertrophy, causing the gland to enlarge. This enlargement is the body's attempt to trap more iodine from the bloodstream and maintain hormone output. In the early phase, this compensation is often successful, and the patient remains euthyroid with a visible goiter (a state sometimes called "simple" or "compensated" goiter).

Over time, if iodine deficiency persists, the gland cannot keep up. The patient transitions from subclinical hypothyroidism (elevated TSH, normal FT4) to overt hypothyroidism (elevated TSH, low FT4). The PNPK Hipotiroid Dewasa 2026 identifies iodine deficiency in endemic GAKI regions as a recognized cause of primary hypothyroidism, noting that prevalence of hypothyroidism increases in areas with iodine deficiency.

Chronically stimulated thyroid tissue also undergoes nodular transformation. Autonomous nodules may develop over decades, sometimes leading to the paradoxical scenario of toxic multinodular goiter (Jod-Basedow phenomenon) if the patient is later exposed to excess iodine. This pathophysiologic link between deficiency, hyperplasia, nodularity, and potential autonomy is a commonly tested concept.

In pregnancy, the demand for iodine increases by roughly 50%, which is why pregnant women in endemic areas are at particularly high risk. The PNPK Hipotiroid Dewasa 2026 notes that hypothyroidism in pregnancy (prevalence approximately 2.5%) carries risks of miscarriage, preterm birth, preeclampsia, and impaired cognitive development of the child.

02Classification and Clinical Manifestation

Goiter Classification

By Stage

03Diagnostic Workup

The best initial test for any patient with suspected thyroid dysfunction, including those from endemic areas, is serum TSH. The PNPK Hipotiroid Dewasa 2026 designates TSH (specifically, sensitive TSH or TSHs) as the first-line screening test for patients with clinical suspicion of hypothyroidism. An elevated TSH points toward primary hypothyroidism, which is the expected consequence of chronic iodine deficiency.

When TSH is elevated, the next step is to measure serum FT4 to classify the severity. If FT4 is normal with an elevated TSH, the patient has subclinical hypothyroidism. If FT4 is low, the patient has overt (clinical) hypothyroidism. The PNPK emphasizes that TSH and FT4 should be checked simultaneously when central hypothyroidism is suspected, but in the setting of endemic goiter, the pattern is almost always primary (high TSH, low FT4).

Urinary iodine concentration is not a routine individual test but is used as an epidemiological marker. In clinical practice, if a patient from an endemic GAKI area presents with goiter and hypothyroidism, the geographic and dietary history itself is highly suggestive. A UIC below 100 mcg/L in a population sample confirms endemic iodine deficiency.

Anti-TPO and Anti-Tg antibodies are important for ruling out Hashimoto thyroiditis. The PNPK Hipotiroid Dewasa 2026 states that these should be checked as follow-up tests in hypothyroid patients when autoimmune thyroiditis is suspected. In endemic goiter, these antibodies are typically negative. A positive result shifts the diagnosis toward autoimmune thyroiditis.

Thyroid ultrasound evaluates gland size, echotexture, and the presence of nodules. The PNPK notes that USG should assess for diffuse enlargement (struma difusa), atrophy, focal lesions, parenchymal echogenicity, homogeneity, and vascularity. In endemic goiter, you expect a diffusely enlarged gland; long-standing cases may show multinodular changes.

Scintigraphy is considered a supplementary test per the PNPK, useful for evaluating uptake patterns, particularly when nodularity is present and autonomous function needs to be assessed.

04Management and Treatment

Management in Detail

Prevention is the most tested concept for endemic goiter. Universal salt iodization is the globally recommended strategy and is the single most effective public health measure against iodine deficiency disorders. The WHO recommends a daily iodine intake of 150 mcg for non-pregnant adults and 250 mcg for pregnant and lactating women. In severely endemic areas, iodized oil (oral or intramuscular) can provide coverage for 6 to 12 months per dose.

For patients who present with a euthyroid goiter from an endemic area, iodine supplementation alone may lead to goiter regression, particularly in younger patients. In older patients with long-standing multinodular goiter, the response to iodine supplementation is limited, and there is a risk of iodine-induced thyrotoxicosis (Jod-Basedow effect). This is a commonly tested point: rapid iodine repletion in a patient with long-standing endemic goiter and autonomous nodules can precipitate hyperthyroidism.

When endemic goiter progresses to hypothyroidism, levothyroxine replacement becomes the standard treatment. The PNPK Hipotiroid Dewasa 2026 provides clear dosing guidance. For uncomplicated adults, the starting dose is 1.6 mcg/kg body weight per day. For elderly patients or those with suspected coronary artery disease, the starting dose is 25 or 50 mcg/day, increased by 25 mcg every 3 to 4 weeks until the target TSH is reached.

Levothyroxine must be taken on an empty stomach, at least 60 minutes before breakfast or at least 3 hours after dinner, to maximize absorption. The PNPK emphasizes that consistency in timing is critical. Dose adjustments are required in patients taking iron, calcium, proton pump inhibitors, sucralfate, or bile acid sequestrants, all of which impair levothyroxine absorption.

Monitoring involves TSH and FT4 evaluation every 4 to 8 weeks after initiating therapy or changing the dose. Once stable, the interval extends to every 6 months, and then to every 12 months. The PNPK warns against overtreating to a TSH below 0.1 mU/L, as this increases the risk of atrial fibrillation, osteoporosis, stroke, and fractures.

For subclinical hypothyroidism in endemic settings, the PNPK recommends a "wait and see" approach when TSH is between 4 and 10 mU/L and the patient is asymptomatic. Treatment is initiated when TSH is at or above 10 mU/L, or when the patient is pregnant or planning pregnancy, has clear hypothyroid symptoms, or carries cardiovascular comorbidities.

In pregnancy, women already on levothyroxine should increase their dose by adding two extra tablets per week upon confirmation of pregnancy. Data cited in the PNPK shows that approximately 70% of pregnant women require a dose increase of about 30% compared to their preconception dose. TSH targets are trimester-dependent: 0.1 to 2.5 mU/L in trimester 1, 0.2 to 3.0 mU/L in trimester 2, and 0.3 to 3.0 mU/L in trimester 3.

Surgical management (total or subtotal thyroidectomy) is reserved for large compressive goiters causing dysphagia, dyspnea, or stridor, and for nodules suspicious for malignancy. Radioactive iodine therapy is an alternative for shrinking large non-toxic goiters in patients who are poor surgical candidates.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common mistake students make on questions about endemic goiter is confusing it with Hashimoto thyroiditis. Both conditions cause goiter and hypothyroidism, and both can present with nearly identical symptoms. The key discriminator is the autoantibody profile: Hashimoto is anti-TPO and anti-Tg positive, while endemic goiter due to iodine deficiency is antibody-negative. The vignette will give you the answer by mentioning geographic clues ("mountainous region," "developing country," "no access to iodized salt," "endemic area") and by stating that thyroid antibodies are negative.

A second common trap involves iodine-induced thyrotoxicosis (Jod-Basedow effect). When a vignette describes a patient from an endemic area who develops palpitations, weight loss, and tremor shortly after receiving iodine supplementation or iodinated contrast, the correct answer is iodine-induced hyperthyroidism, not Graves disease. This occurs because autonomous nodules within a long-standing endemic goiter respond to sudden iodine availability by producing excess thyroid hormone unregulated by TSH feedback.

A third pearl relates to screening at primary care level. The PNPK Hipotiroid Dewasa 2026 recommends the Billewicz Index scoring system for use in primary care facilities (FPKTP) that lack laboratory access. A score above +25 indicates a high probability of hypothyroidism and warrants referral for TSH measurement. A score below -30 makes hypothyroidism unlikely. This clinical scoring tool bridges the diagnostic gap in resource-limited settings and is worth knowing for exam scenarios set in primary care or rural environments.

Finally, remember the pregnancy angle. The PNPK emphasizes that hypothyroidism in pregnancy, whether from endemic goiter or other causes, increases risks of miscarriage, preterm delivery, preeclampsia, postpartum hemorrhage, low birth weight, and impaired cognitive development. The target TSH in pregnancy is trimester-adjusted and lower than in the general population. Failing to lower the TSH target for pregnant patients is a frequent source of wrong answers.

The core competency tested in endemic goiter questions is the ability to recognize the geographic and dietary context of iodine deficiency, differentiate it from autoimmune thyroiditis using antibody status, understand the stepwise workup from TSH to FT4 to antibodies to imaging, and apply the correct management strategy (iodine supplementation for prevention, levothyroxine for treatment of hypothyroidism).